General Information
Bempedoic Acid API is a novel small molecule inhibitor of triphosphate-citrate lyase (ACL). It is indicated as an adjunctive therapy, along with diet and statin treatment, for adults with refractory hypercholesterolemia. By blocking cholesterol synthesis in the liver, Bacid effectively reduces LDL-C levels, mitigating the risk of atherosclerotic plaques and cardiovascular events. It was approved for use by the FDA in 2020, along with a combination product Bempedoic Acid and Ezetimibe.
1.typo 2. please add this remark to the other pages [LS1]
About the API
- Japan DMF
- Korea DMF
- US DMF
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.